Yasmin Siddiqui, DO
Adult Medicine · Coral Springs, FLNPI 1194041665
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,829, 7.9 times the $231 reported in 2019.
Across 122 payments — averaging $30.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$403
- Boehringer Ingelheim$374
- E.r. Squibb & Sons, L.L.C.$372
- Novo Nordisk$322
- Medtronic$315
- Pfizer$222
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,750100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 13 | $403 |
| Boehringer Ingelheim | 8 | $374 |
| E.r. Squibb & Sons, L.L.C. | 10 | $372 |
| Novo Nordisk | 12 | $322 |
| Medtronic | 2 | $315 |
| Pfizer | 11 | $222 |
| AstraZeneca | 4 | $188 |
| Heartflow, Inc. | 4 | $183 |
| Abbott | 1 | $164 |
| Cvrx, Inc. | 3 | $162 |
| Amgen | 12 | $155 |
| Corcept Therapeutics | 5 | $129 |
| Lantheus Medical Imaging, Inc. | 5 | $83 |
| Boston Scientific | 4 | $82 |
| Exact Sciences | 3 | $73 |
| Bayer | 2 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| Saluda Medical Americas, Inc. | 1 | $47 |
| Agepha Pharma FZ LLC | 2 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $38 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Baxter Healthcare | 2 | $33 |
| Lilly USA, LLC | 2 | $33 |
| GSK | 2 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Preventice Services, LLC | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Vivus LLC | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$229
- COBALT DR MRI SURESCAN$168
- CardioMEMS HF System$164
- PERCEPTA QUAD CRT-P MRI SURESCAN$147
- FFRct$147
- Barostim Neo System$130
- XARELTO$124
- WAINUA$120
- ELIQUIS$116
- CAMZYOS$109
How this compares
$3,750 in reported general payments places this provider in the 85th percentile of 195 adult medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 554 | $469,383 |
| EntrestoSacubitril/Valsartan | 210 | $174,209 |
| XareltoRivaroxaban | 115 | $119,002 |
| JardianceEmpagliflozin | 81 | $58,597 |
| OzempicSemaglutide | 43 | $46,643 |
| MounjaroTirzepatide | 26 | $28,084 |
| Repatha SyringeEvolocumab | 21 | $14,696 |
| FarxigaDapagliflozin Propanediol | 18 | $11,361 |
| BrilintaTicagrelor | 14 | $10,526 |
| Atorvastatin Calcium | 406 | $4,507 |
| Metoprolol Succinate | 488 | $4,381 |
| Rosuvastatin Calcium | 407 | $4,322 |
| Torsemide | 157 | $3,847 |
| Ranolazine ErRanolazine | 24 | $2,716 |
| Carvedilol | 249 | $1,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $222 | $469,383554 claims |
| NovartisEntresto | $16 | $174,209210 claims |
| Johnson & JohnsonXarelto | $403 | $119,002115 claims |
| Boehringer IngelheimJardiance | $374 | $58,59781 claims |
| Novo NordiskOzempic | $322 | $46,64343 claims |
| Lilly USA, LLCMounjaro | $33 | $28,08426 claims |
| AstraZenecaFarxiga, Brilinta | $188 | $21,88732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 195 adult medicine providers in Florida.
Other adult medicine in Coral Springs
- Joshua RycusCoral Springs$13K
- Angela Fernandez SantiagoCoral Springs$3K
- Asha GuptaCoral Springs$991
- Steven SantiagoMiami$290K
- Tammy DsouzaKissimmee$191K
- Eric SchertzerPlantation$26K
- Ricardo SerranoMerritt Island$20K
- Marlene JarinMiami Beach$18K
- Myra ReedPanama City Beach$16K
- Frederick WeigandDeltona$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.